5-HT2 receptors modulate the expression of antipsychotic-induced dopamine supersensitivity

European Neuropsychopharmacology

Volumn 25, Issue 12, 2015, Pages 2381-2393

  Charron, Alexandra ^a   Hage, Cynthia El ^a   Servonnet, Alice ^a   Samaha, Anne Noël ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

5 HT2 receptors; Amphetamine; Antipsychotic medication; Dopamine supersensitivity; Locomotor activity; Schizophrenia

Indexed keywords

AMPHETAMINE; DOPAMINE; HALOPERIDOL; RITANSERIN; SEROTONIN 2 RECEPTOR; SEROTONIN 2A RECEPTOR; VOLINANSERIN; CENTRAL STIMULANT AGENT; NEUROLEPTIC AGENT; PROTEIN BINDING; SEROTONIN RECEPTOR AFFECTING AGENT; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CINGULATE GYRUS; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOMOTOR ACTIVITY; PUTAMEN; RAT; RECEPTOR DENSITY; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; DRUG ADMINISTRATION ROUTE; DRUG EFFECTS; LOCOMOTION; METABOLISM; RADIOASSAY; SPRAGUE DAWLEY RAT;

AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; HALOPERIDOL; LOCOMOTION; MALE; PROTEIN BINDING; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN, 5-HT2; SEROTONIN AGENTS; TRITIUM;

EID: 84952639597     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.10.002     Document Type: Article

References (65)

1. Aghajanian G.K., Marek G.J. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 1997, 36:589-599.
2. Ase A.R., Amdiss F., Hebert C., Huang N., van Gelder N.M., Reader T.A. Effects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin1A receptors. J. Neural Transm. 1999, 106:75-105.
3. Asper H., Baggiolini M., Burki H.R., Lauener H., Ruch W., Stille G. Tolerance phenomena with neuroleptics catalepsy, apomorphine stereotypies and striatal dopamine metabolism in the rat after single and repeated administration of loxapine and haloperidol. Eur. J. Pharmacol. 1973, 22:287-294.
4. Ball K.T., Rebec G.V. Role of 5-HT2A and 5-HT2C/B receptors in the acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on striatal single-unit activity and locomotion in freely moving rats. Psychopharmacology 2005, 181:676-687.
5. Basura G.J., Walker P.D. Serotonin 2A receptor mRNA levels in the neonatal dopamine-depleted rat striatum remain upregulated following suppression of serotonin hyperinnervation. Brain Res. Dev. Brain Res. 1999, 116:111-117.
6. Basura G.J., Walker P.D. Serotonin 2A receptor regulation of striatal neuropeptide gene expression is selective for tachykinin, but not enkephalin neurons following dopamine depletion. Brain Res. Mol. Brain Res. 2001, 92:66-77.
7. Bedard A.M., Maheux J., Levesque D., Samaha A.N. Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues. Neuropsychopharmacology 2011, 36:1248-1259.
8. Bedard A.M., Maheux J., Levesque D., Samaha A.N. Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia. Schizophr. Bull. 2013, 39:692-702.
9. Bishop C., Daut G.S., Walker P.D. Serotonin 5-HT2A but not 5-HT2C receptor antagonism reduces hyperlocomotor activity induced in dopamine-depleted rats by striatal administration of the D1 agonist SKF 82958. Neuropharmacology 2005, 49:350-358.
10. Bishop C., Tessmer J.L., Ullrich T., Rice K.C., Walker P.D. Serotonin 5-HT2A receptors underlie increased motor behaviors induced in dopamine-depleted rats by intrastriatal 5-HT2A/2C agonism. J. Pharmacol. Exp. Ther. 2004, 310:687-694.
11. Blomeley C., Bracci E. Excitatory effects of serotonin on rat striatal cholinergic interneurones. J. Physiol. 2005, 569:715-721.
12. Blue M.E., Yagaloff K.A., Mamounas L.A., Hartig P.R., Molliver M.E. Correspondence between 5-HT2 receptors and serotonergic axons in rat neocortex. Brain Res. 1988, 453:315-328.
13. Bortolozzi A., Diaz-Mataix L., Scorza M.C., Celada P., Artigas F. The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J. Neurochem. 2005, 95:1597-1607.
14. Brown P., Gerfen C.R. Plasticity within striatal direct pathway neurons after neonatal dopamine depletion is mediated through a novel functional coupling of serotonin 5-HT2 receptors to the ERK 1/2 map kinase pathway. J. Comp. Neurol. 2006, 498:415-430.
15. Burnet P.W., Eastwood S.L., Harrison P.J. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 1996, 15:442-455.
16. Cheng Y.F., Paalzow L.K. Linear pharmacokinetics of haloperidol in the rat. Biopharm. Drug dispos. 1992, 13:69-76.
17. Chouinard G., Jones B.D., Annable L. Neuroleptic-induced supersensitivity psychosis. Am. J. Psychiatry. 1978, 135:1409-1410.
18. Clow A., Jenner P., Marsden C.D. Changes in dopamine-mediated behaviour during one year's neuroleptic administration. Eur. J. Pharmacol. 1979, 57:365-375.
19. De Deurwaerdere P., Spampinato U. Role of serotonin(2A) and serotonin(2B/2C) receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. J. Neurochem. 1999, 73:1033-1042.
20. El Hage C., Bédard A.M., Samaha A.N. Chronic antipsychotic treatment leading to dopamine supersensitivity persistently alters nucleus accumbens function. Neuropharmacology 2015, Epub ahead of print.
21. Fallon P., Dursun S., Deakin B. Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients. Ther. Adv. Psychopharmacol. 2012, 2:13-22.
22. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry 1992, 49:538-544.
23. Farde L., Wiesel F.A., Halldin C., Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiatry 1988, 45:71-76.
24. Farde L., Wiesel F.A., Sedvall G. D1- and D-2 dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 1989, 99. Suppl:S28-31.
25. Ferguson M.C., Nayyar T., Ansah T.A. Reverse microdialysis of a 5-HT2A receptor antagonist alters extracellular glutamate levels in the striatum of the MPTP mouse model of Parkinson's disease. Neurochem. Int. 2014, 71:36-46.
26. Filip M., Bubar M.J., Cunningham K.A. Contribution of serotonin (5-hydroxytryptamine; 5-HT) 5-HT2 receptor subtypes to the hyperlocomotor effects of cocaine: acute and chronic pharmacological analyses. J. Pharmacol. Exp. Ther. 2004, 310:1246-1254.
27. Gianutsos G., Drawbaugh R.B., Hynes M.D., Lal H. Behavioral evidence for dopaminergic supersensitivity after chronic haloperidol. Life Sci. 1974, 14:887-898.
28. Gill K.M., Cook J.M., Poe M.M., Grace A.A. Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia. Schizophr. Bull. 2014, 40:341-350.
29. Graff-Guerrero A., Mizrahi R., Agid O., Marcon H., Barsoum P., Rusjan P., Wilson A.A., Zipursky R., Kapur S. The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology 2009, 34:1078-1086.
30. Ichikawa J., Meltzer H.Y. The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo. Brain Res. 1992, 574:98-104.
31. Kankaanpaa A., Meririnne E., Lillsunde P., Seppala T. The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens. Pharmacol. Biochem. Behav. 1998, 59:1003-1009.
32. Kapur S., Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry 2001, 50:873-883.
33. Kapur S., VanderSpek S.C., Brownlee B.A., Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther. 2003, 305:625-631.
34. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 2000, 157:514-520.
35. Kudo S., Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin. Pharmacokinet. 1999, 37:435-456.
36. Lanteri C., Salomon L., Torrens Y., Glowinski J., Tassin J.P. Drugs of abuse specifically sensitize noradrenergic and serotonergic neurons via a non-dopaminergic mechanism. Neuropsychopharmacology 2008, 33:1724-1734.
37. Leysen J.E., Niemegeers C.J., Van Nueten J.M., Laduron P.M. [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol. Pharmacol. 1982, 21:301-314.
38. Lucas G., De Deurwaerdere P., Caccia S., Umberto S. The effect of serotonergic agents on haloperidol-induced striatal dopamine release in vivo: opposite role of 5-HT(2A) and 5-HT(2C) receptor subtypes and significance of the haloperidol dose used. Neuropharmacology 2000, 39:1053-1063.
39. Masand P.S., Roca M., Turner M.S., Kane J.M. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim. Care Companion J. Clin. Psychiatry 2009, 11:147-154.
40. Meltzer H.Y., Matsubara S., Lee J.C. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol. Bull. 1989, 25:390-392.
41. Millan M.J., Brocco M., Gobert A., Joly F., Bervoets K., Rivet J., Newman-Tancredi A., Audinot V., Maurel S. Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat. Eur. J. Neurosci. 1999, 11:4419-4432.
42. Miner L.A., Backstrom J.R., Sanders-Bush E., Sesack S.R. Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex. Neuroscience 2003, 116:107-117.
43. Montanaro N., Dall'Olio R., Gandolfi O., Vaccheri A. Differential enhancement of behavioral sensitivity to apomorphine following chronic treatment of rats with (-)-sulpiride and haloperidol. Eur. J. Pharmacol. 1982, 81:1-9.
44. Moser P.C., Moran P.M., Frank R.A., Kehne J.H. Reversal of amphetamine-induced behaviours by MDL 100,907, a selective 5-HT2A antagonist. Behav. Brain Res. 1996, 73:163-167.
45. Muller P., Seeman P. Brain neurotransmitter receptors after long-term haloperidol: dopamine, acetylcholine, serotonin, alpha-noradrenergic and naloxone receptors. Life Sci. 1977, 21:1751-1758.
46. Navailles S., De Deurwaerdere P. Presynaptic control of serotonin on striatal dopamine function. Psychopharmacology 2011, 213:213-242.
47. Palfreyman M.G., Schmidt C.J., Sorensen S.M., Dudley M.W., Kehne J.H., Moser P., Gittos M.W., Carr A.A. Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function. Psychopharmacology 1993, 112:S60-67.
48. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, Sydney; Orlando. 2nd ed.
49. Pierce R.C., Rowlett J.K., Bardo M.T., Rebec G.V. Chronic ascorbate potentiates the effects of chronic haloperidol on behavioral supersensitivity but not D2 dopamine receptor binding. Neuroscience 1991, 45:373-378.
50. Riahi G., Morissette M., Parent M., Di Paolo T. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias. Eur. J. Neurosci. 2011, 33:1823-1831.
51. Samaha A.N., Reckless G.E., Seeman P., Diwan M., Nobrega J.N., Kapur S. Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol. Psychiatry 2008, 64:145-152.
52. Samaha A.N., Seeman P., Stewart J., Rajabi H., Kapur S. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J. Neurosci. 2007, 27:2979-2986.
53. Sayers A.C., Burki H.R., Ruch W., Asper H. Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine. Psychopharmacologia 1975, 41:97-104.
54. Seeman P., Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975, 188:1217-1219.
55. Sengupta P. The laboratory rat: relating its age with human's. Int. J. Prev. Med. 2013, 4:624-630.
56. Smith R.C., Davis J.M. Behavioral supersensitivity to apomorphine and amphetamine after chronic high dose haloperidol treatment. Psychopharmacol. Commun. 1975, 1:285-293.
57. Smith R.C., Davis J.M. Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine, and thioridazine. Life Sci. 1976, 19:725-731.
58. Suzuki T., Kanahara N., yamanaka H., Takase M., Kimura H., Watanabe H., Lyo M. Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatry Res. Epub 2015.
59. Tadokoro S., Okamura N., Sekine Y., Kanahara N., Hashimoto K., Iyo M. Chronic Treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr. Bull 2011.
60. Tauscher J., Jones C., Remington G., Zipursky R.B., Kapur S. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 2002, 7:317-321.
61. Wadenberg M.L., Kapur S., Soliman A., Jones C., Vaccarino F. Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology 2000, 150:422-429.
62. Woerner M.G., Kane J.M., Lieberman J.A., Alvir J., Bergmann K.J., Borenstein M., Schooler N.R., Mukherjee S., Rotrosen J., Rubinstein M., et al. The prevalence of tardive dyskinesia. J. Clin. Psychopharmacol. 1991, 11:34-42.
63. Yan Q., Reith M.E., Yan S. Enhanced accumbal dopamine release following 5-HT(2A) receptor stimulation in rats pretreated with intermittent cocaine. Brain Res. 2000, 863:254-258.
64. Zayara A.E., McIver G., Valdivia P.N., Lominac K.D., McCreary A.C., Szumlinski K.K. Blockade of nucleus accumbens 5-HT2A and 5-HT2C receptors prevents the expression of cocaine-induced behavioral and neurochemical sensitization in rats. Psychopharmacology 2011, 213:321-335.
65. Ziance R.J., Sipes I.G., Kinnard W.J., Buckley J.P. Central nervous system effects of fenfluramine hydrochloride. J. Pharmacol. Exp. Ther. 1972, 180:110-117.